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Abstract
A workshop to discuss anti-inflammatory approaches in the treatment of CF was held at Novartis
Institutes for Biomedical Research (NIBR, Horsham, UK) in March 2008.
Key opinion leaders in the field (Hugo De Jonge, Stuart Elborn, Erich Gulbins, Mike Konstan,
Rick Moss, Scott Randell and Adriano Rossi), and NIBR scientists were brought together to
collectively address three main aims: (i) to identify anti-inflammatory targets in CF, (ii) to
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evaluate the pros and cons of targeting specific cell types and (iii) to discuss model systems to
profile potential therapeutic agents.
The highlights of the workshop are captured in this review.
Introduction
Cystic fibrosis (CF) is the most common lethal genetic disease in Caucasians affecting
approximately 1 in 3000 individuals. It is an autosomal recessive disease involving a
mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) chloride ion
channel, the gene for which was discovered in 1989 (1). It is a multi-system disorder, with
onset in childhood. Morbidity includes pancreatic insufficiency, GI/nutritional deficiencies
including an inability to secrete digestive enzymes and critically, pulmonary disease. In the
vast majority of cases mortality results from respiratory failure, with the median age of
survival having increased to approximately 37 years, while the median age at death has
remained at 25.2 years (2).
The classical paradigm for pulmonary morbidity in CF is that as a result of inadequate
CFTR function, impaired mucociliary clearance develops which leads to infection and
inflammation (3). Inflammation in the CF lung occurs early in life: In foetal and infant
airways, with neutrophils predominating in the cellular infiltrate (4). This inflammatory
response to infection is excessive relative to the burden of bacteria (5), with the major
colonising pathogen in CF being Pseudomonas aeruginosa (Staphylococcus aureus and
Haemophilus influenzae can also be present), (6). In addition, viral infections, eg:
respiratory syncitial virus, have the potential to impair host defence to bacterial infection in
CF patients by damaging the epithelium and further impairing mucociliary clearance.
Release of elastase and other proteinases from neutrophils is considered to be a key
contributor to lung damage associated with the inflammatory response. In healthy
individuals, constitutive anti-proteases complex with proteinases and shield the lung against
their activity. In CF, the activity of elastase and other proteinases are significantly elevated
and overwhelm this protective mechanism (7). However, the concept that infection precedes
inflammation is now being questioned; the Cftr mutation itself may directly induce
inflammation prior to infection.
Role of Neutrophils in CF Inflammation
The primary function of the neutrophil is in host defence; phagocytosing and destroying
invading pathogens. Specifically the neutrophil generates reactive oxygen species via
NADPH oxidase (8) and secretes anti-microbial granular proteins including elastase (six
elastase genes are known to exist, with elastase 2 being the most prominent in human
neutrophils (9), collagenase, cathepsins and myeloperoxidase (10) to perform this protective
role. The release of DNA from neutrophils can form neutrophil extracellular traps (NETS) in
which Gram −ve and Gram +ve bacteria can be bound and killed (11;12). However, if this
response is not controlled, excessive tissue damage can result, accounting for much of the
lung damage and destruction observed in CF. Under the hypoxic conditions found in CF
mucus, neutrophils are thought to live longer, and thus their potential to damage the lung is
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enhanced (13). As a result, strategies to target the neutrophil and its destructive potential
have emerged as key therapeutic approaches to CF lung disease. These include inhibition of
neutrophil recruitment, activation, release/activation of degranulation products, digestion of
DNA and targeted removal of unwanted neutrophils by apoptosis (14;15).
To inhibit pro-inflammatory signalling, the use of broad spectrum anti-inflammatory drugs
such as oral corticosteroids (16;17) and non-steroidal anti-inflammatory agents such as
ibuprofen (18) have been examined in CF. Disappointingly, the beneficial effects of oral
corticosteroids are limited and adverse side-effects are prominent. Inhaled corticosteroids
have no demonstrable beneficial effects in CF patients, although these clinical studies were
only of a short duration and had small numbers of patients (19). It has been suggested that
corticosteroids can delay neutrophil apoptosis (20); an effect which may explain the limited
efficacy of corticosteroids in CF. Ibuprofen is used clinically to treat CF and has been
demonstrated to slow the rate of decline in FEV1; most dramatically in younger patients
(21), but the beneficial effect of this treatment in CF is not widely accepted and there are
concerns regarding clinical safety that have hindered its use. In addition to broad spectrum
anti-inflammatory agents, the clinical efficacy of several compounds targeting specific
neutrophil associated pro-inflammatory mediators have been examined, a notable example
of which is the trial of BIIL 284 BS, a LTB4 receptor antagonist. In this trial, CF patients
treated for 24 weeks with the drug developed pulmonary exacerbations at twice the
frequency of the placebo group, resulting in early termination of the trial (22). Whether or
not the occurrence of pulmonary exacerbations reflects the concept that LTB4 inhibition is
detrimental in CF, or is a compound-related phenomenon is unclear. Unfortunately no
assessment of bacterial counts, inflammatory cells, or mediators have been reported from
this study. This highlights the need for detailed biomarker assessment (from sputum,
bronchoalveolar lavage (BAL), urine, etc) during clinical studies, in order to monitor factors
that may be useful as early indicators of potential exacerbations, and also to gain
information related to drug mechanism of action (23). However, selecting samples for
biomarker assessment has its challenges. While sputum is generally easy to obtain and non-
invasive, it can be difficult to obtain from paediatric patients and biomarker assessment can
be variable. BAL is an attractive alternative as samples can be obtained from all age groups,
fewer patients are required, and a single lung lobe/segment can be evaluated several times,
but it is invasive and expensive to perform and may yield local rather than generalized
findings. Serum and urine samples may not be suitable for biomarker assessment if
inflammation is confined to the lung. In sputum from CF patients, neutrophil elastase has
been demonstrated to provide the best correlate with lung function (24).
Another approach to targeting inflammation in CF is the neutralization of neutrophil
activation products. Potential therapeutic agents which have been proposed include anti-
elastases, other protease inhibitors (25), DNAse and antioxidants (26). The DNAse
Pulmozyme is used clinically in CF patients to reduce mucous viscosity and thus aid
mucociliary clearance. Indeed there is clinical evidence to suggest that this therapy improves
lung function and decreases the incidence of pulmonary exacerbations (27;28).
Novel strategies to promote neutrophil apoptosis are also emerging. For example, cyclin-
dependent kinase (CDK) inhibitor drugs, such as R-roscovitine, can induce caspase-
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dependent apoptosis per se and importantly inhibit the delay in neutrophil apoptosis induced
by survival agents in vivo (29). Indeed, in three mouse models, a carrageenan model of acute
pleurisy, a bleomycin model of lung inflammation and a passively-induced arthritis model,
R-roscovitine has been demonstrated to promote the resolution of neutrophillic
inflammation (29). Roscovitine has yet to be profiled in bacterial infection models.
In summary, the neutrophil is a promising target in CF due to its significant contribution
towards the lung pathology of the disease, its tractable nature and because much is known
about its behaviour and function. However, the difficulty of selectively targeting this cell
type may be challenging. In addition, other cell types clearly contribute to the inflammation
in CF lung disease and thus selective inhibition of the neutrophil alone may not be
sufficiently efficacious. There are also inevitable concerns about compromising host defence
in CF patients, given that this is the primary function of this cell type.
Role of Epithelial Cells in CF Inflammation
The airway epithelium actively participates in innate immunity and orchestrates
inflammatory responses. This is in addition to its well-characterised role in regulating
airway surface liquid volume and hydration, which is essential for normal mucus clearance.
In CF, due to inadequate chloride ion transport and the resultant increased activity of the
epithelium sodium channel (ENaC), there is inadequate airway surface liquid hydration (30).
Over-expression of the βENaC subunit in the mouse (Scnn1b) results in animals that exhibit
some of the key abnormalities of cystic fibrosis including airway obstruction (as a
consequence of increased mucus secretion and impaired mucociliary clearance) and the
development of spontaneous neutrophilic lung inflammation and prolonged eosinophilia
(31). These findings support the concept that ENaC inhibition may be a potential therapy in
CF and therefore suggest that CFTR is not the only ion channel target in the epithelium.
The airway epithelium recognises and responds to inflammatory stimuli via the interaction
of various ligands with innate immune system receptors including the tolllike receptors
(TLRs); TLR2 (ligands include lipopeptides, peptidoglycan, lipoteichoic acid (32), CXCR1
fragments (33) and TLR5 (only known ligand is flagellin (34) are considered to be of
particular importance. The role of airway epithelial TLR4 (potential endogenous ligands
include lipopolysaccharide and heat shock proteins (35; 36) is controversial, although
sentinel cells such as macrophages and dendritic cells may respond strongly to TLR4 ligands
and secrete factors affecting epithelial cells, creating dynamic interactions. P. aeruginosa
products acutely activate TLRs although chronic exposure of epithelial cells to this pathogen
leads to adaptation and tolerance (37). The induction of mRNA for pro-inflammatory
cytokines, including IL-8, ENA-78, MCP-1, MIP-3α and GRO-α decreases after chronic
bacterial product exposure. However, cytokine protein production from epithelial cells
following repeated P. aeruginosa challenge does not necessarily decrease, which may
explain sustained inflammation in the CF airway. Pro-inflammatory cytokine secretion is
also enhanced in proportion to the degree of mechanical wounding in vitro, and epithelial
damage suffered during a pulmonary exacerbation will likely increase airway inflammation.
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Airway epithelium controls lung inflammation and injury through the NF-κB pathway, as
demonstrated in a mouse modular transgenic system in which NF-κB activation resulted in
inflammation and progressive lung injury (38). Also, inhibition of NF-κB attenuated LPS-
induced inflammation and epithelial damage (39). Targeting this signalling pathway in the
epithelium may be an effective anti-inflammatory strategy. However a caveat of this
approach is that NF-κB is a key pathway in the induction of immune responses to P.
aeruginosa and its inhibition could therefore impact host defence (40).
Key questions remain regarding anti-inflammatory approaches in CF. When is inflammation
greater than necessary to confine infection, and can we exploit intrinsic anti-inflammatory
regulatory mechanisms to develop novel and more specific therapies?
Role of Lymphocytes in CF Inflammation
Although the neutrophil is widely recognised as a key player in CF inflammation, a
lymphocytic infiltrate is also seen in the CF lung (41;42). In CF, lymphocytes are activated
at all stages of the disease and in people of all ages, and increased B-cell aggregates
(CD20+) are found in the peribronchiolar tissue together with increased CD3+ T-cells in
distal bronchiolar tissue and parenchyma from CF patients versus healthy lung tissue (42).
CFTR is functionally expressed in lymphocytes, and in cells from CF patients the
characteristic defect in the CFTR channel is observed; this can be reversed by anti-sense or
wt CFTR (43-45). These cells also possess an alternative to the cAMP-dependent pathway
for CFTR activation, which is nitric oxide/cGMP-dependent (46).
The finding that mitogen-activated CF T cell clones are skewed towards a Th2 phenotype
compared to controls implicates Th2 pathways in CF. These activated T cell clones secrete
50% less IL-10 compared to controls (47) and also ∼80% less IFNγ following T cell
receptor activation (48). Interestingly IL-10 but not IFN-y secretion is inhibited by chloride
channel blockade. Moreover, activated peripheral blood mononuclear cells from P.
aeruginosa infected CF patients have reduced IFNγ and increased IL-4 secretion compared
to uninfected CF patients (49). In CF patients chronically infected with P. aeruginosa, there
is an increase in CD4+CCR4+ Th2-cells in the lung compared to CF patients without P.
aeruginosa infection (50). Based on preclinical models and correlative clinical data it was
hypothesized that treatment of CF patients with the Th1 cytokine, IFNγ might reduce the
inflammatory response to P. aeruginosa; however a controlled clinical trial with inhaled
IFNγ1b showed no significant improvement in FEV1 or alteration in sputum cytokines (51).
With the description of a Th17 T cell population, the question has arisen as to whether CF is
in fact a Th17-mediated disease. Indeed, IL-17A released from CD4+ T cells is crucial for
neutrophil recruitment in response to gram negative bacterial infection (Figure 1). This is in
part via induction of CXC chemokines (42). Additionally, IL-23p19, IL-22, IL-17A and
IL-17F levels have been demonstrated to be elevated in sputum from adult and pediatric CF
patients undergoing pulmonary exacerbation (53;54). IL-17A and IL-17F may regulate
matrix metalloproteinases, and speculatively this may underlie bronchiectasis in CF.
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The pathogenesis of inflammation and subsequent lung injury in CF, involves crosstalk
between epithelium, T lymphocytes and neutrophils, all of which are potential targets for
selective pro-inflammatory pathway inhibitors (Figure 2).
Model systems for profiling anti-inflammatory agents in CF
Model systems for profiling anti-inflammatory compounds in CF include cultured primary
cells or cell lines, human lung xenografts in severe combined immunodeficiency (SCID)
mice and CF animal models in species such as the mouse, ferret and pig.
In cultured cells and cell lines, it is questionable as to whether the CF inflammatory state can
be fully reproduced. In addition cultured cells and cell lines can respond differently to
stimuli compared to primary cells. Although both cultured cells and cell lines can
demonstrate spontaneous activation of NFκB (55), higher expression of pro-inflammatory
mediators (56-58) and a greater inflammatory response to P. aeruginosa exposure (59),
there are often minimal differences in the gene expression profile between CF and non-CF
cells. In addition, increased expression and secretion of pro-inflammatory mediators are not
always present or inducible by P. aeruginosa (60). These discrepancies may arise due to
selection and passaging of cells and also differences in P. aeruginosa strain variants,
exposure times etc. Nasal brushings obtained from patients or healthy volunteers are a
source of primary cells that can be cultured to create pseudostratified mucociliary epithelium
(61). This strategy has demonstrated phenotypic differences between airway epithelial cells
from healthy volunteers and COPD patients, with greater IL-8 release in response to LPS
treatment from the latter.
Grafting of human foetal airways into SCID mice has shown characteristics of the CF
airway, such as increased IL-8 content in airway surface liquid and an influx of mouse
leukocytes to the airway epithelium (62). Although these characteristics make it an attractive
model, it is limited by the poor availability of foetal CF lungs.
Pig and ferret have 91-92% CFTR sequence homology and similar lung structure and
physiology with human. The pig in particular has been successfully used to model many
diseases and may provide an interesting opportunity to gain new insights into the
pathogenesis of CF (63). However, despite the many CF-relevant similarities between
human and pig lungs (anatomy, histology, electrolyte transport, submucosal gland function
and immune and inflammatory responses), it is still unclear whether a CF pig will develop
lung disease with features similar to that seen in human CF (63). The utility of this species
may also be limited by expense and logistical implications. While the mouse has only 78%
sequence homology to human, mouse models are available for all classes of Cftr mutation
except class V. Mouse models are also easier to produce/acquire than pig and ferret models,
however there are a number of issues relating to using the mouse. For example, there are
differences between mouse and human epithelial cell morphology and physiology,
specifically the distribution of submucosal glands. In addition CF mice rarely display
spontaneous lung inflammation, although there have been notable exceptions in animals
overexpressing the βENaC subunit (31) and those homozygous for the ΔF508 Cftr mutation
(64). Compared to wild type control animals, the latter also exhibited increased
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susceptibility to infection induced by intratracheal instillation of lipopolysaccharide from P.
aeruginosa (65). The use of some CF mice is further hampered by poor fertility and high
mortality. Indeed, despite the βENaC overexpressing mouse exhibiting many of the key
abnormalities of CF, a postnatal mortality of ∼50% at 4 weeks of age may limit the use of
these animals for the evaluation of potential therapeutic interventions. Additionally, in a
more recent publication overexpression of βENaC has been shown to cause emphysema (66)
Cross-breeding of CF mice with other genetically modified mice has highlighted the
potential importance of other gene products, such as acid-sphingomyelinase (67), in the
pathogenesis of CF. In this study, compared to wild type animals, epithelial cells from Cftr
deficient mice were found to have higher levels of ceramide, which increased with age and
were predominantly found in large airways. Ceramide accumulation in intracellular vesicles,
as well as at the apical membrane of epithelial cells, occurs as a result of elevated pH
resulting in the net increased production of ceramide via an imbalance of the acid
sphingomyelinase and acid ceramidase activities. It is proposed that elevated ceramide
levels lead to airway inflammation due to apoptosis of epithelial cells and deposits of DNA
and mucus, as well as the release of pro-inflammatory mediators. This in turn leads to
increased susceptibility to P. aeruginosa infections. By crossing these Cftr deficient mice
with an acid sphingomyelinase heterozygous mouse, lung ceramide levels were normalized.
In addition treatment of the mice with amitriptyline, a known acid sphingomyelinase
inhibitor, had the same result. In Cftr deficient mice, an increase in bacterial load in the lung
is observed 2 hours post P. aeruginosa infection versus wild type. This increased bacterial
load is reduced by treatment with amitriptyline and also in Cftr deficient mice crossed with
acid sphingomyelinase heterozygous mice (67). It is possible that normalisation of ceramide
levels may represent a novel means of preventing bacterial infection in CF patients. In the
future, cross-breeding of CF mice with NF-κB reporter mice, which permit the detection of
NF-kB activation by bioluminescence (68;69), may provide further insight into the pro-
inflammatory state of mouse CF models, the impact of bacterial infection and the efficacy of
anti-inflammatory therapies.
Proof of Concept study designs
Drug development is becoming an increasingly expensive and challenging undertaking (70),
and the “Proof of Concept” (PoC) study is occupying an increasingly important place in the
drug development paradigm. Proof of concept can be thought of as demonstration of a
meaningful biological activity in man. A successful proof of concept study generates
confidence in the ultimate therapeutic potential of a compound and often triggers additional
development activities such as large-scale production, additional preclinical safety studies,
and later-phase clinical studies. By performing a proof of concept study early in the
development of a compound there is also an opportunity to halt development in light of a
negative outcome, allowing transfer of resources and activities to more promising
compounds and therapeutic approaches.
Demonstration of biological activity in a proof of concept study is achieved through
measurement of a biomarker. A biomarker is a characteristic that is objectively measured as
an indicator of normal biological processes, pathogenic processes, or a pharmacological
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response to a therapeutic intervention (71). Biomarkers can be observable characteristics
(e.g. height), quantifiable changes at the protein, mRNA, or DNA level, or readily
measurable clinical parameters. Successful registration of a therapeutic compound requires
demonstration of improvement in a clinical endpoint, a characteristic or variable that reflects
how a patient feels, functions or survives. A surrogate endpoint, a biomarker that is intended
to substitute for a clinical endpoint, is expected to predict clinical benefit (or harm or lack of
benefit/harm) based on epidemiologic, therapeutic, pathophysiologic or other scientific
evidence.
There are several characteristics of an ideal proof of concept study that increase its appeal in
the drug development paradigm. The study should be of short duration, such as a single dose
or at most a few weeks of repeated dosing. The target population should be focused, with a
small sample size. Measurable, robust biomarkers that correlate with a relevant clinical
(registration) outcome are highly desired. Finally, the study should enable intelligent Go/No
Go decisions for the compound. Thus a successful proof of concept study design results in
limited exposure of human subjects to the compound while providing a rapid readout for
decision making.
There are several design elements that should be considered when planning a proof of
concept study for an anti-inflammatory compound in cystic fibrosis. These include the
duration of dosing, the patient population, the choice of endpoints (biomarkers) that reflect
the mechanism of action and correlate with a relevant clinical outcome, and the selection of
safety biomarkers. The ideal proof of concept study would involve two to four weeks of
dosing in a limited number of patients with a change in an inflammatory biomarker
predictive of clinical efficacy serving as the primary outcome measure. The likelihood of
success in employing a study design such as this can be predicted by a thorough preclinical
understanding of the pharmacokinetic-pharmacodynamic relationship of the compound,
although as noted above there are several shortcomings in current preclinical models of CF
that reduce the ability to optimize this prediction.
At present, the most critical impediment to designing an ideal proof of concept study for an
anti-inflammatory therapy in CF is the lack of an inflammatory biomarker that has been
shown to be predictive of clinical efficacy. This is not surprising given the limited anti-
inflammatory therapeutic arsenal employed in CF care. Oral corticosteroid therapy in CF
was preceded by clinical studies that examined clinical endpoints rather than biomarkers
(72), and subsequent studies also failed to identify a relevant biomarker while revealing
toxicity that limited widespread use (11). Ibuprofen is another anti-inflammatory therapy
with clinical utility in CF (12, 15). While ibuprofen therapy has been shown to decrease the
influx of neutrophils in oral wash samples (73), this potential biomarker, and indeed the
therapy itself, has not been widely adopted. Examples of potential inflammatory biomarkers
in CF that could be considered in designing a proof of concept study include neutrophil
count and cytokine levels in induced sputum (23;24), cytokine levels or C-reactive protein in
serum (74), and desmosine in urine (75), although none of these have been shown to predict
clinical efficacy for a therapeutic compound. Continued efforts to identify informative
inflammatory biomarker(s) in CF are thus sorely needed. Finally, the need for reliable safety
biomarkers in trials of anti-inflammatory therapies in CF is highlighted by the report of an
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increased incidence of pulmonary exacerbations in CF patients receiving BIIL284-BS, an
oral leukotriene B4 receptor antagonist (22). This report underscores the potential risks of
anti-inflammatory therapy in this patient population.
Summary
Inflammation in cystic fibrosis involves multiple inflammatory cells types, including
neutrophils, lymphocytes and epithelial cells. The use of broad-spectrum anti-inflammatory
agents is one approach to modulate inflammation in CF, however corticosteroids show only
limited improvements in FEV1. Also noteworthy is the modest improvement in FEV1
observed in patients treated with the broad spectrum macrolide antibiotic, azithromycin (76)
which has been shown to have anti-inflammatory effects, although the mechanism(s)
underlying this activity remain unclear (77). There are however, several proposed
mechanisms for the anti-inflammatory effects of macrolides including: suppression of
production and secretion of pro-inflammatory cytokines (via ERK1/2 inhibition and
activation), down-regulation of adhesion molecules and promoting inflammatory cell
apoptosis (78).
Targeting the neutrophil specifically is a promising approach due to the lung pathology seen
in CF, which is clearly associated with an excessive neutrophil influx and activation,
coupled with poor neutrophil clearance. Conversely however, this strategy has the potential
to compromise host defence given the key role that neutrophils contribute to innate host
defence. Targeting the epithelial cell or lymphocyte may also be beneficial given their
potential roles in orchestrating the inflammatory response in the CF lung.
In order to profile potential novel anti-inflammatory targets appropriate model systems are
required. Cell lines are useful to screen compounds against certain targets, however a caveat
is that only certain aspects of the CF inflammatory state can be reproduced. For target
validation and screening of the most promising strategies, the mouse and potentially in the
future the ferret and pig could provide suitable disease models. Translation of these
preclinical findings into effective anti-inflammatory therapies in the clinic will ultimately
benefit from continued attempts to identify inflammatory translational biomarkers predictive
of clinical efficacy.
Targeting inflammation in CF would seem to be an attractive approach to the treatment of
this disease, but obtaining sufficient anti-inflammatory efficacy versus impairing host
defence remains a key challenge.
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Figure 1. IL-17-induced neutrophil recruitment in CF
Production of Interleukin (IL)-6, transforming growth factor (TGF)-β and IL-23 by airway
dendritic cells (DC) following activation by bacterial pathogens promotes Th17 cell
differentiation. The release of IL-17A and IL-17F from these cells acts on airway epithelial
cells to release neutrophil chemokines IL-6. IL-8 and growth related oncogene (GRO)-α.
ICAM-1, intracellular adhesion molecule-1; MPO, myeloperoxidase; MMP, matrix
metalloprotease.
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Figure 2. Overview of potential anti-inflammatory strategies for the treatment of cystic fibrosis
CF, cystic fibrosis; CFTR cystic fibrosis transmembrane conductance regulator; ENaC,
epithelium sodium channel; TLR toll-like receptor, NFκB, nuclear factor kappa B; LTB4,
leukotriene B4; ROS, reactive oxygen species; NETS, neutrophil extracellular traps; CDK1,
cyclin dependent kinase 1.
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